Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX: PXS) technology. In August, 2021 Aptar signed an exclusive option agreement to Pharmaxis’ “Orbital” technology, handing over USD $250,000. Now, a little under a year later, Aptar is deploying USD $2.5 million to exercise the
Read More
The world’s most lucrative healthcare market is quickly appreciating Aussie pharmaceuticals company Pharmaxis (ASX: PXS) whose cystic fibrosis (CF) treatment Bronchitol is rapidly emerging as the preferred treatment by CF sufferers in the United States. Researched and manufactured in Australia, Bronchitol gained commercial approval from the US Food and Drug Administration (FDA) in October 2020
Read More